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Another propensity score analysis compared SBRT with 
sublobar resection for stage I NSCLC in patients at high risk 
for lobectomy (8). In 53 matched pairs the difference in 
overall survival was not significant and the cumulative 
incidence of cause-specific death was comparable between 
both groups. Conclusion of this study was that SBRT can be an 
alternative treatment option to sublobar resection for 
patients with severe comorbidity who cannot tolerate 
alobectomy due to functional impairment (8).  
In June 2015 the “Comité del’Evolution des Pratiques en 
Oncologie (CEPO) from Québec, Canada published 
recommendations regarding the use of SBRT (9). For 
medically operable patients with T1-2N0M0 NSCLC surgery 
remains the standard treatment due to the lack of high-level 
evidence and valid comparative data. For medically 
inoperable patients withT1-2N0M0 NSCLC or medically 
operable patients who refuse surgery, SBRT should be 
preferred to external beam radiotherapy. In the latter cases 
a biological equivalent dose (BED) of at least 100 Gy should 
be administered. The choice ofusing SBRT should be 
discussed within a multidisciplinary tumor board. 
Radiotherapy should not be considered for patients whose life 
expectancy is very limited because of comorbidities.  
In summary, main points are: 
· surgical resection remains the treatment of choice for 
operable early-stage NSCLC  
· SBRT may be considered for functionally compromised 
patients who cannot tolerate lobectomy.  
· further high-level evidence is needed which requires close 
cooperation between radiation oncologists and thoracic 
surgeons to design comparative trials with clear inclusion 
criteria and unequivocal definitions of endpoints.  
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Debate: Is brachytherapy the best for partial breast 
irradiation?  
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Accelerated Partial Breast Irradiation (APBI) using 
multicatheter brachytherapy is an attractive treatment 
approach not only to shorten the course of radiation therapy 
from 3-6 weeks to 2-5 days but also to reduce significantly 
the radiation exposure to the breasts, the skin, the lung and 
particularly to the heart very effectively.  
Over the last 20 years different modalities of APBI have been 
introduced into clinical practice –multicatheter 
brachytherapy, single catheter brachytherapy, IORT 
techniques, different techniques of External Beam Radiation 
Therapy (EBRT). Unfortunately fact is that the results of APBI 
trials with IORT using intraoperative electrons or 50 kV 
photons have been negative. As well Vaidya et al. (TARGIT 
trial) as Veronesi et al. (ELIOT trial) reported high 5-year 
recurrence rate after IORT, namely 3.3%-4.4% in IORT groups 
versus statistically significant lower recurrence rates in 
control groups 0.4%-1.3%. Possibility of APBI using EBRT is of 
course very attractive, since this technique is broadly 
available and easy to perform. Unfortunately, hitherto 
reported results of phase 3 APBI trials using EBRT are either 
disappointing (RAPID trial) or with low statistical power 
(Olivotto et al., Livi et al.). On the contrary, during the last 
decade number of modern phase 2 and phase 3 APBI trials, 
using multicatheter interstitial brachytherapy for the delivery 
of APBI, have demonstrated favorable long-term local control 
rates and cosmetic outcomes, comparable to the results of 
whole breast irradiation (WBI). In the largest phase 3 
randomized non-inferiority GEC-ESTRO trial with sufficient 
statistical power (~1200 pts.), importantly using for APBI 
solely multicatheter interstitial brachytherapy in 5 days, 
after median follow-up of 6.6 years the 5-year local 
recurrence rates were 1.4% in the APBI arm, and 0.9% in the 
WBI arm (p=0.4), and 5-year disease-free and overall survival 
were 96-97% in the WBI group versus 97% in the APBI group - 
all events are without any statistical and clinical significance. 
The equivalence of local recurrence rates was evident in all 
age groups, in all histological subgroups and also independent 
of the type of systemic therapy. Thus it´s the first phase 3 
study proving non-inferiority of APBI in comparison to whole 
breast irradiation for selected early stage breast cancer 
patients. Undoubted is, that in the light of the landmark UK 
and Canadian trials comparing 5 versus 3 weeks of WBI the 
difference in total treatment time between WBI and APBI 
using multicatheter brachytherapy (4-5 days) has been 
partially diminished. However the difference between 3 
weeks of WBI versus 4-5 days of APBI still remains clinically 
and socio-economically relevant. Moreover, due to the 
extreme steep fall-off of dose of Iridum-192, the significant 
dose reduction of irradiated normal tissues (including the 
heart and skin) is a unique advantage of interstitial 
multicatheter brachytherapy, which is hardly ever achievable 
by other APBI techniques. The remaining, hitherto 
unreported ongoing APBI trials unfortunately use for APBI 
only different techniques of EBRT. The results of these trials 
will therefore particularly contribute to further fine-tuning of 
selection criteria and to precise requirements for quality 
assurance of EBRT-based APBI.  
In summary: At the present time only the long-term results of 
APBI using sole multicatheter brachytherapy for appropriate 
selected patients demonstrate impressive low local 
recurrence rates – similar as WBI, accompanying with 
excellent radiation protection of surrounding organs – better 
as WBI. Consequently “APBI used multicatheter 
brachytherapy is today a proven and valid alternative 
treatment option after breast conserving surgery, and can be 
offered for all low risk breast cancer patients in clinical 
routine”. 
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Over the past ten years the results of several clinical trials 
have been published, detailing various approaches of PBI. 
Among the different techniques used, IORT has increased 
rapidly in popularity, mainly in Europe, and up to date many 
thousands of women have been treated in clinical setting. 
IORT allows to realize a radiation dose to the index quadrant, 
eliminating the treatment to the tissue remote from the 
tumour bed, and using only one very high dose (20 Gy or 
more) in a single session. When single doses above certain 
thresholds of 10 Gy are given, some additional biological 
effects on tumor cell killing and from the surrounding 
microenvironment can be expected. IORT also represents the 
possibility of overcoming some constraints such as the 
accessibility to the centres of radiotherapy, the socio-
economic impact on the working life and on the personal 
habits of the patient. Another important advantage is the 
avoidance of the interactions with the systemic therapy, that 
may determine delays in the initiation or in the carrying out 
of the adjuvant treatment. These potential benefits must be 
balanced with the potential higher risk of recurrence within 
the untreated gland tissue in the same breast as well as the 
still unknown long-term results on survival and cosmesis. Two 
prospective randomized clinical studies establishing the role 
of IORT in clinical practice have been published up to now. A 
single-center study, named ELIOT, was performed at the 
European Institute for Oncology (EIO) in Milan, Italy. Patients 
with limited size tumor (2.5 cm) and age of 48 years or more 
were either randomized to a single dose of 21 Gy of IORT 
with electrons or to standard WBI. The local recurrence rate 
(LRR) at 5-years was higher in the experimental arm (4.4% 
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versus 0.4%), and just fell within the pre-defined non-
inferiority margin of 4.5%. However, in patients with low risk 
factors like suggested by the ESTRO or ASTRO consensus’ 
criteria, there were not statistically different LLRs in both 
arms, and also in patients with luminal A molecular subtype 
the LLR was very low in the IORT arm, about 1%. It was also 
found that there was no significant difference in the 5-year 
overall survival rate in two arms, that is, 96.8% in the ELIOT 
arm and 96.9% in the EBRT arm. For patients with higher risk 
factors, a new strategy has been now developed, which 
include a hypofractionated WBI to be given after surgery and 
ELIOT. The TARGIT-A trial was a multicentric trial. The 
inclusion criteria were stricter than in the ELIOT trial. It 
included patients with unifocal small breast cancer with non-
lobular histology and tested the concept of risk-adapted 
single-dose IORT, which was followed by external-beam WBI 
in patients with additional unfavorable risk factors. The 
latest published results from the TARGIT-A trial, with a 
median follow-up of 2 years and 4 months, reported a LRR 
with IORT of 3.3% and with EBRT of 1.3, meeting the non-
inferiority margin of 2.5%, set at the outset. Overall, breast 
cancer mortality in the IORT arm was 2.6% versus 1.9% in the 
WBI arm. In addition, non-breast cancer deaths were found to 
be significantly reduced in the IORT arm: 1.4% versus 3.5%, 
with p = 0.0086. Toxicity and cosmesis were assessed by 
different methods in the studies, but in any case a favorable 
outcome has been shown. The comparison between the 
current standard or alternative PBI approaches for early stage 
breast cancer with data coming IORT techniques poses a 
dilemma as to when preliminary results are sufficiently 
mature to be allow practitioners and patients to consider a 
new treatment approach as safe. We know that most data 
from studies of breast conservation therapy have 
demonstrated the importance of long-term data (up to 20 
years) in determining the ultimate efficacy of a treatment. 
The level 1 randomized evidence produced by the IORT trials 
show that this technique is very convenient for the patient, 
effective and has few side effects, rather than any 
postoperative treatment or procedures. Patients have every 
right to be offered an informed choice. 
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Several clinically controlled randomized trials on accelerated 
partial breast irradiation (APBI) are currently being 
conducted and some of these have now published results. 
The trials have used different strategies, for example 
different patient selection criteria, doses and number of 
fractions, overall treatment time, treated volume and 
radiation techniques. Many trials have compared the APBI 
treatment to whole breast irradiation (WBI) 50 Gy/25 fr 
followed by a boost. External beam APBI is an attractive 
strategy, because every radiation department will be able to 
do the dose planning. The demand for technical skills is in 
principle not higher than for conventional dose planning. Few 
randomized trials have reported data, but unfortunately the 
largest one has not been promising.  
In the phase III randomized RAPID trial significantly worse 
cosmetic outcome was reported with median follow up 36 
months in 2135 patients randomized 1:1 to APBI based on 3D-
CRT with 38.5 Gy/10 fractions, 5 days, versus WBI based on 
42.5Gy/16 fr or 50Gy/25 fr +/-boost. Adverse cosmesis was 
higher in APBI-treated patients compared with WBI patients 
as assessed by trained nurses (29% vs 17%; p=0.001) and by 
patients (26% vs 18%; p=0.02). Grade 3 adverse events were 
seen in 1.4% of APBI patients, and not in WBI patients. With 
median 5 years follow up data from another phase III trial 
involving 520 patients randomized to APBI with IMRT using 30 
Gy/5 fr versus WBI using 50 Gy/25 fr + boost has been 
reported by Livi and coworkers. Significantly better results 
were seen in APBI patients regarding acute (p=0.0001), late 
(p=0.004) and cosmetic morbidity (p=0.045). Local 
recurrence was seen in 1.5% of the patients. Thus data from 
large phase III trials supporting routine use of external beam 
APBI at the present time are not available. However, it is to 
be expected that the UK IMPORT LOW Trial will be able to 
report data from >2000 patients with median 5 years follow 
up at the Early Breast Cancer Conference (EBCC) March 2016. 
In that trial the strategy is based on 40 Gy/15 fr in all 3 arms, 
where arm 1 is WBI, arm 2 is partial breast irradiation, and 
arm 3 has a gradual dose using 40 Gy/15 fr to partial volume 
and 36 Gy/15 fr to residual breast. At EBCC, data on 
morbidity will also be reported from the DBCG PBI trial, 
which has included >800 patients and randomized them to 
APBI versus WBI using 40 Gy/15 fr in both arms. Data from 
these 2 trials will be presented and discussed at ESTRO 35. If 
the results from the IMPORT LOW Trial show that PBI using 40 
Gy/15 fr is safe, and these data are supported by results from 
the DBCG PBI trial using the same treatment, then there is 
support for the statement that IMRT is the best for PBI. 
However, we are also awaiting results from the ongoing 
NSABP B-39/RTOG 0413 trial, which has accrued >4000 
patients, who were randomized to APBI versus WBI. The 
majority of patients in the APBI arm have been treated with 
3D-CRT. Many of the APBI trials were designed and initiated a 
decade ago, where the local recurrence risk was higher than 
we see today. Therefore some of these trials are 
underpowered to support the statement they are 
investigating. It is to be expected that results from several 
trials investigating external APBI will be published in the near 
future, and hopefully results from the trials will be included 
in meta-analyses to achieve enough statistical power to 
identify subgroups of patients where APBI is safe and other 
subgroups where WBI is to be preferred. 
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Partial breast irradiation (PBI) can be performed with various 
techniques including both brachytherapy (BT) and external 
beam radiotherapy (EBRT). These methods differ from each 
other regarding technical skill and dosimetric characteristics. 
Recent developments in imaging, dose calculation algorithms 
and beam delivery techniques have made all methods 
clinically feasible, but in most institutions the applied 
method mostly depends on the physician's preference and the 
technical availability.  
Among all techniques the longest experience exists with 
multicatheter interstitial BT which can provide highly 
conformal dose distribution, large dose gradient at target 
edge, but it is quite complex and requires certain manual 
skilfulness. The possible geometric miss can result in 
significant under dosage of the target.  
Technically, the intracavitary applicators are easier to be 
used and with balloon-type applicators no geometric miss can 
occur, but proper tissue conformance is not always 
guaranteed. In dosimetric point of view drawbacks of the 
Mammosite applicator are the spherical dose distribution, the 
symmetric margin and the potential high dose to skin, lungs 
and ribs. In some anatomical situation the balloon can be 
asymmetric resulting in asymmetric target coverage. The 
multichannel applicators are more flexible regarding shaping 
the dose distribution and reducing dose to critical structures 
without compromising the target volume coverage. With 
these applicators asymmetric margins can be used to a small 
degree.  
In intraoperative electronic BT using spherical applicators 
the dose distribution is also spherical and a large dose 
inhomogeneity develops due to the sharp dose fall-off of the 
low energy X-ray beam. The margin is always symmetric, but 
the geometric accuracy is always ensured.  
At intraoperative irradiation with electron beams there is 
no 3D-defined target volume, modulation possibilities to 
shape the dose distribution are very limited and conformal 
radiotherapy cannot be performed.  
Linear accelerator based EBRT techniques expose relatively 
large volumes of non-target breast to high dose mainly due to 
the extended target volume created from CTV. In three-
dimensional conformal radiotherapy (3D-CRT) dose to 
contralateral breast, lung or heart can be reduced with 
